Cryoport (CYRX) Projected to Post Earnings on Tuesday

Cryoport (NASDAQ:CYRX) is expected to post its quarterly earnings results after the market closes on Tuesday, March 4th. Analysts expect Cryoport to post earnings of ($0.33) per share and revenue of $58.71 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Cryoport Trading Down 1.4 %

Shares of CYRX stock opened at $5.57 on Friday. Cryoport has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock’s fifty day moving average is $7.45 and its two-hundred day moving average is $7.68. The firm has a market capitalization of $275.33 million, a P/E ratio of -1.65 and a beta of 1.59.

Insider Activity

In other news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the transaction, the director now owns 59,497 shares of the company’s stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CYRX shares. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Roth Mkm decreased their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.29.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.